// App-Quantinova.ai

BSH2020‐OR‐011 : A phase 2 open‐label study of danicopan (ACH‐0144471) in patients with paroxysmal nocturnal haemoglobinuria who have an inadequate response to eculizumab monotherapy

Researchers

Presenter

  • A. Kulasekararaj

Principal Investigators

  • A. Risitano

  • J. Maciejewski

  • R. Notaro

  • P. Browett

  • J. W. Lee

  • M. Huang

  • M. Geffner

  • R. Brodsky

Medical Centers

  • Haematology, Kings College Hospital, London,

  • Clinical Medicine and Surgery, Federico II University of Naples, Napoli, Italy

  • Translational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH

  • Core Research, Instituto per lo Studio, la Prevenzione e la Rete Oncologica

  • Hematology, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy

  • Molecular Haematology and Laboratory Medicine, University of Auckland, Auckland, Australia

  • Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, Korea, Republic of (South)

  • Discovery, Achillion Pharmaceuticals, New Haven

  • Clinical Development, Medical Affairs, Achillion Pharmaceuticals, Blue Bell

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Locations

  • United Kingdom

  • Italy

  • United States

  • Australia

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Pulmonary arterial hypertension

  • Hypertension

Biomarkers

  • Cluster of Differentiation 55

  • Cluster of differentiation 59

  • Fibroblast growth factor receptor 3

  • Soluble Complement 5b-9

  • Red Blood Cells

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved